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Introduction
The inability to attain or maintain a penile erection sufficient for sexual intercourse is a common problem experienced by a third of men over the age of 40 years. 1 
Erectile dysfunction (ED)
is a debilitating disease which can have profound psychological effects on personal relationships and the social well-being of the affected individual. The diagnosis and evaluation of sexual dysfunction has been well described, and several validated algorithms are available to quantify the classification and severity.
The International Index of Erectile Function (IIEF) and the Sexual
Health Inventory for Men questionnaires are commonly used in the initial assessment of ED. 2 Several risk factors have been linked to the pathophysiology of ED. Endothelial damage has been the focus of many recent studies. An evaluation of the cardiovascular status, in addition to the administration of questionnaires to men with ED, might reduce mortality and improve sexual quality of life. 3 The mechanism of an erection The effect of serotonin on erectile function involves sympathetic, parasympathetic and somatic outflow mechanisms, and is considered to exert a general inhibitory effect on male sexual behaviour.
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Causes of erectile dysfunction
As with most diseases, ED can be attributed to organic (physical) and non-organic (psychological) causes, but is often the result of a combination of both. 6 Traditionally, physical causes refer to vasculogenic, neurogenic or endocrinological disorders (Table I ) and should be differentiated from other male sexual dysfunctions, such as premature ejaculation, Peyronie's disease (anatomical causes) and disorders of orgasm. The absence of morning erections, muscle pain and cramps relieved by rest and numbness in the saddle area might indicate a physical cause and should be thoroughly investigated.
Psychogenic causes are mostly the result of depression, low selfimage, relationship conflict and a stressful lifestyle, which, in turn, lead to performance anxiety and a reduction in the desire to be intimate. ED is known to be associated with certain drugs 7 (Table   II) . Identifying the cause and assessing the risk factors may be beneficial in reducing the mortality as a result of other medical conditions, and in particular, cardiovascular disease, where endothelial cell damage is the first event in the atherosclerotic process. 3, 8 The famous phrase "ED equals endothelial damage, which equals early death" is taught to medical students around the world in an attempt to emphasise the importance of reducing cardiovascular risk factors, which might start off by an undiagnosed patient presenting with ED.
Treatment options
Several treatment options for ED are available. They consist of mechanical devices (vacuum pumps and constriction rings), surgical interventions (prosthetic penile implants, arterial reconstruction and venous blocking procedures), and pharmacological management (PDE-5 inhibitors, testosterone replacement therapy and invasive prostaglandin administration). 9 The current approach to management aims to identify the underlying cause. Lifestyle interventions and limiting cardiovascular risk factors, such as smoking, hypertension, dyslipidaemia and obesity, should be advocated. Psychotherapy alone, or in combination with psychoactive drugs and PDE-5 inhibitors, should be prescribed when depression or anxiety is the primary cause. 10 When a selective serotonin reuptake inhibitor is implicated as a possible cause, the appropriate addition of buproprion could be considered. 11 First-line medical therapy with a PDE-5 inhibitor is recommended because of its efficacy, favourable side-effect profile and ease of use. Men with low serum testosterone levels should additionally receive hormonal replacement therapy, unless there are contraindications. 12 Second-line treatment is reserved for men who do not respond to PDE-5 inhibitors. Available options include noninvasive vacuum devices and invasive alprostadil administration (intracavernosal injection or intraurethral suppository). 13 Surgical interventions, such as prosthetic penile implantations and revascularisation procedures, are mainly reserved for failed first-and second-line responses. 14 
Phosphodiesterase-5 inhibitors
Currently, there are four available registered PDE-5 inhibitors, i.e. sildenafil, vardenafil, tadalafil and avanafil. The latter was only approved for registration and prescription in the USA from 2012, and in Europe, Australia and New Zeanland from 2013. South African registration was still pending at the time of submission of this article. PDE-5 inhibitors share a similar mechanism of action and general side-effect profile. However, individual agents have distinct pharmacokinetic and pharmacodynamic properties, which facilitate the tailoring of sexual therapy according to patients' needs. 15 These agents do not cause tumescence in the absence The page number in the footer is not for bibliographic referencing www.tandfonline.com/oemdAvanafil Avanafil is the newest PDE-5 inhibitor. It exhibits enhanced PDE-5 selectivity compared to the other available PDE-5 inhibitors, thereby displaying a more favourable side-effect profile. It has a rapid onset of action, and is the only PDE-5 inhibitor specifically indicated for ED in men > 65years of age. 18 Table III provides a comparative summary of currently available PDE-5 inhibitors.
Testosterone replacement therapy
Administering testosterone in the absence of low testosterone levels may be ineffective in treating ED and increases the risk of hepatic and prostate cancer. Testosterone replacement therapy should only be initiated in men with serum testosterone levels ≤ 12 nmol/l, indicative of testosterone deficiency syndrome. 19 Low levels of testosterone in the presence of raised prolactin, abnormal follicle-stimulating hormone or luteinising hormone, thyroid-stimulating hormone, thyroxine and cortisol should be evaluated by an endocrinologist for specialist care.
There is a strong association between metabolic syndrome and testosterone deficiency syndrome. 4 This necessitates the routine evaluation of testosterone levels in all patients with features of cardiovascular disease and diabetes mellitus, regardless of the presence or absence of ED. 20 Long-acting testosterone undecanoate 1 000 mg [Nebido ® , Bayer HealthCare, single exit price (SEP) of R1 636.09 for 1 000 mg] may be injected 4-5 times per year, and shows a significant improvement in libido, morning erections, mood changes and depressive symptoms. Shorteracting testosterone cypionate 200-400 mg (Depo-Testosterone ® , Pfizer, SEP of R337.29 for 1 000 mg) can be injected every 3-4 weeks in patients where cost is an issue, but does not provide the favourable physiological profile associated with the longacting agent.
Intracavernosal prostaglandin injections
Alprostadil (Caverject ® , Pfizer, SEP of R166.17 for 20 µg) is indicated as the second-line treatment when PDE-5 inhibitors fail, or patients experience an unsatisfactory response. 7 Failure is regarded as the inability to attain or maintain an adequate erection on at least four successive occasions while on optimal PDE-5 inhibitor drug dosing. Alprostadil may be preferred in men with spinal cord injuries or post radical prostatectomy.
The intracavernosal injection of alprostadil blocks the inhibitory effect of the sympathetic nervous system, and acts as a direct smooth muscle vasodilator, causing an increase in blood flow to the penis. A predictable, sustainable erection is achieved within 10 minutes, and is independent of sexual stimulation. Compliance is the largest indicator for discontinuation, and patients need adequate counselling before commencing treatment. Sideeffects include pain at the site of injection, hypotension and priapism, and penile fibrosis, if not administered correctly.
Conclusion
ED is a common condition and is vastly undertreated. Healthcare providers need to be familiar with all of the currently available treatment options. Association with an increased risk of cardiovascular disease and mortality should make physicians more vigilant and proactive with regard to the management of ED. Serum testosterone levels should be regularly checked in men with features of metabolic syndrome and ED. Stigma around the condition should be eliminated by proper education.
Patients should be encouraged to report any symptoms to their healthcare provider, including primary care workers and pharmacists, who are in a position to adequately refer them to a physician. Mass media campaigns and government initiatives may improve cardiovascular mortality by creating public awareness concerning the health risks associated with ED.
